Side-by-side · Research reference
CerebrolysinvsChonluten
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BAnimal-MechanisticHUMAN-REVIEWED8/38 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
01Mechanism of Action
Parameter
Cerebrolysin
Chonluten
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
Bronchial epithelial cells and respiratory mucosa tissue complexes
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
—
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
—
02Dosage Protocols
Parameter
Cerebrolysin
Chonluten
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Evidence basis
Phase 3 RCT + observational
In vitro mechanistic
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Typical protocol dose
—
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
Frequency
—
Once or twice daily
Route
—
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
Clinical validation
—
None (PubMed indexed)
04Side Effects & Safety
Parameter
Cerebrolysin
Chonluten
Injection site reaction
Mild pain, erythema (IM route)
—
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
—
Seizure risk
Not elevated; safe in epilepsy populations
—
Documented adverse events
—
No published safety data in PubMed-indexed literature
Theoretical risks
—
Peptide hypersensitivity, GI intolerance (uncharacterized)
Drug interactions
—
Unknown — no pharmacokinetic studies available
Pregnancy / lactation
—
No data — avoid
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Chonluten
- ·Known hypersensitivity to peptide components
Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
05Administration Protocol
Parameter
Cerebrolysin
Chonluten
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
Chonluten
— no documented stacks